---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-089978"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:09:24.103422+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma receives Nasdaq minimum bid price deficiency notice; has until Dec 17, 2025 to cure

## Summary
- Nasdaq notified Sutro on June 20, 2025 of non-compliance with $1.00 minimum bid price rule.
- Company has 180 calendar days, until December 17, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.
- If not cured, Sutro may transfer to Nasdaq Capital Market for a second 180-day period or face delisting.
- Sutro plans to monitor bid price and may implement a reverse stock split if needed.

## SEC filing metadata
- accession: 0000950170-25-089978
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017025089978/0000950170-25-089978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017025089978/stro-20250620.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-089978
- JSON: https://secwatch.observer/filing/0000950170-25-089978.json
- Plain text: https://secwatch.observer/filing/0000950170-25-089978.txt

## Key facts
- Listing & Compliance Notices
  SUTRO BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: June 20, 2025, Sutro Biopharma, Inc. (the “Company”) received written notice from The NASDAQ Stock Market, LLC (“NASDAQ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until December 17, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017025089978/0000950170-25-089978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.